Learn of and follow our journey to bring about Therapeutic Mitochondria Transfer as a new treatment modality
cellvie AG is proud to announce that CEO Dr. Alexander Schueller placed amongst the Top-17 contenders for the prestigious De Vigier Entrepreneurship Award.
Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer
CELLVIE palces among the final 5 contenders for the grant prize of the MedTech Innovator Award and takes home the prestigious MedTech Innovator Value Award
cellvie has been granted orphan-drug designation for the use of mitochondria in the prevention of ischemia-reperfusion injury during solid organ transplantation.